DB05441ExperimentalOrganism Based Therapies
AVAC is derived from M. vaccae. It has been tested in uses related to asthma and in treating eczema and atopic dermatitis. Mycobacterium vaccae is a non-pathogenic, saprophytic bacteria whose... Mycobacterium vaccae is a non-pathogenic, saprophytic bacteria whose antigens can be used to induce peripheral immune activation through the activity of regulatory T-cells that surpress inappropriate Th2 activity.
- Mechanism
- Curator reviewed
Induces peripheral immune activation through the activity of regulatory T-cells that surpress inappropriate Th2 cytokeine activity.
- Primary indication
- Investigated for use/treatment in asthma and atopic dermatitis.Curator reviewed
Resolves to
Targets
What you can answer from here — as of July 03, 2026
1Protein targetEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with AVAC, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account